SystImmune expands its iza-bren programme again
Relapsed biliary tract cancer, and ASCO, beckon.
Ominous signs for EGFR degraders
BeOne's degrader BG-60366 appears to have been discontinued.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Rakuten sheds light on its conjugate
The company secures funding to push its lead candidate towards US approval.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
